Table 2 Main course of cryoglobulinemia vasculitis features after anti-CD20 antibody (rituximab) infusion
No. of patients positive at baselineNo. of patients with available data at follow upPatients with available data at follow up (%)
Vasculitis:
Skin involvement4840
    CR–2767.5
    PR–512.5
    NR–820.0
Arthralgia3534
    CR–1852.9
    PR–926.5
    NR–720.6
Neuropathy3129
    CR–931.0
    PR–1862.1
    NR–26.9
Glomerulonephritis1818
    CR–1266.6
    PR–316.7
    NR–316.7
Cryoglobulin5722*
    CR–1672.7
    PR–29.1
    NR–418.2
Follow up after rituximab therapy:
    Duration (months), mean (range)57569.7 (0.3–24)
    Relapses–14 out of 3639

  • *The serum cryoglobulin status at the end of follow-up was available in 22 patients.

  • CR, complete response; NR, non-response; PR, partial response.